Kura Oncology, Inc. - KURA Earnings per share for the last twelve months

Official company branding of Kura Oncology (KURA)

High R&D costs and stringent FDA oversight create significant barriers to entry for Kura Oncology, Inc. (KURA). The TTM net income per share reflects business dynamics amid a fierce struggle with pharma behemoths for leadership in targeted therapy, while the value of -3.31 captures the metric level. Operational stability is ensured by strict adherence to regulations during the transportation of biological substances.

KURA Kura Net earnings per one share for the last twelve months (07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for Kura Oncology, Inc. (KURA)

- current quotes and average value forecast:
Analysis of all company metrics:KURA - Kura Oncology
Mass-produced product of Kura

Trailing twelve-month net earnings per share measures the portion of total income attributable to a single security, allowing for an assessment of real business efficiency without accounting for capital dilution. By analyzing the change in per-share profit over the last 12 months on GURU.Markets, an investor sees the current value of -3.31, which in the case of Kura Oncology, Inc. (KURA) depends critically on the trial results of oncology inhibitors.